{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/7283333",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 7283333,
    "resourceId" : "21412232",
    "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
    "authors" : [ "Swen J J", "Nijenhuis M", "de Boer A", "Grandia L", "Maitland-van der Zee A H", "Mulder H", "Rongen G A P J M", "van Schaik R H N", "Schalekamp T", "Touw D J", "van der Weide J", "Wilffert B", "Deneer V H M", "Guchelaar H-J" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ "Animals", "Aryl Hydrocarbon Hydroxylases", "Cytochrome P-450 CYP2C9", "Drug Administration Schedule", "Drug-Related Side Effects and Adverse Reactions", "Humans", "Pharmaceutical Preparations", "Pharmacogenetics", "Practice Guidelines as Topic" ],
    "month" : 5,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "662-73",
    "pgkbPublication" : false,
    "pubDate" : "2011-05-01T00:00:00-07:00",
    "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
    "type" : "Article",
    "version" : 2,
    "volume" : "89",
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"}, {"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"} ],
    "year" : 2011
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166104991",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166104991",
    "name" : "Annotation of DPWG Guideline for abacavir and HLA-B",
    "cancerGenome" : false,
    "descriptiveVideoId" : "",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1183704435,
      "date" : "2011-08-10T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450414978,
      "date" : "2019-05-23T11:11:09.217-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450815696,
      "date" : "2019-09-25T14:04:52.813-07:00",
      "description" : "Changes based on August 2019 guidelines",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450956260,
      "date" : "2020-01-31T13:13:12.226-08:00",
      "description" : "Updated link to 2011 DPWG methods",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/7283333","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":7283333,"resourceId":"21412232","title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","objCls":"Literature","type":"Article","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}]}, {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}]}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA448004",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448004",
      "name" : "abacavir",
      "version" : 9
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA35056",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA35056",
      "symbol" : "HLA-B",
      "name" : "major histocompatibility complex, class I, B",
      "version" : 40
    } ],
    "source" : "Dutch Pharmacogenetics Working Group",
    "summaryMarkdown" : {
      "id" : 1447982006,
      "html" : "<p>Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are &quot;HLA-B*57:01-positive&quot;).</p>\n",
      "version" : 1
    },
    "summaryVideoId" : "",
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1447982005,
      "html" : "<h3 id=\"august-2019-update\">August 2019 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 recommends avoiding abacavir.</p>\n<p><em>Wording in table taken from the <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf\" target=\"_blank\">Dutch guidelines August 2019 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>\n</thead>\n<tbody>\n<tr><td>HLA-B*5701</td><td>abacavir</td><td>HLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir.</td><td>Abacavir is contra-indicated for HLA-B*5701-positive patients.<br/>1. Avoid abacavir.</td></tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0002356.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 and give the same recommendation as in 2011.</p>\n<p><em>Wording in table taken from the <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>\n</thead>\n<tbody>\n<tr><td>HLA-B*5701</td><td>abacavir</td><td>HLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir.</td><td>Abacavir is contra-indicated for HLA-B*5701-positive patients.<br/>1. Advise the prescriber to prescribe an alternative according to the current guidelines.</td></tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0002356.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 [Article:<a href=\"/pmid/21412232\">21412232</a>]. They conclude that an alternate drug should be selected for patients who are HLA-B*57:01 positive.</p>\n<table class=\"table\">\n<thead>\n<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>\n</thead>\n<tbody>\n<tr><td>HLA-B*57:01</td><td>Select alternative drug</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x109/l; leucopenia &lt; 1.0x109/l; thrombocytopenia &lt; 25x109/l; life-threatening complications from diarrhea.</td></tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods</a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;good quality.&quot;</li>\n<li>S: statistically significant difference.</li>\n</ul>\n",
      "version" : 11
    },
    "userId" : "lester",
    "version" : 21,
    "xrefs" : [ ]
  }
}